Saturday 17 October 2026
Export ACAD’s income statement to Excel — free account
ACADIA Pharmaceuticals Inc.
ACAD Healthcare Biotechnology
ACADIA Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.1 billion, up 11.9% from fiscal 2024. In the quarter to June 2026, revenue grew 16.4%, EPS grew 12.5% and free cash flow grew 50.3%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.
19.12
0.59
−2.99%
Follow ACAD
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 13.49 | 11.51 |
Piotroski F-Score |
3 | 5 | 6 | 6 | 4 | 4 | 4 | 5 | 4 | 6 |
Altman Z-Score |
44.08 | 39.37 | 16.22 | 42.35 | 29.17 | 10.59 | 3.00 | 6.38 | 3.41 | 7.90 |
P/S ratio |
192.33 | 29.87 | 9.15 | 18.57 | 19.04 | 7.74 | 5.10 | 6.96 | 3.17 | 4.20 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 25.96 | 0.00 |
Altman Z″-Score (non-manufacturers) |
9.95 | (2.80) | 1.95 | 5.27 | (1.37) | (3.21) | (9.19) | (6.64) | (0.05) | 3.79 |
Beneish M-Score |
250.24 | 1.51 | (2.50) | (2.44) | (2.69) | (2.32) | (3.42) | (2.45) | (2.27) | (0.89) |
P/Operating CF |
(54.47) | (124.79) | (52.38) | (211.98) | (305.98) | (162.02) | (110.62) | 59.21 | 75.31 | (92.28) |
P/B ratio |
6.43 | 11.13 | 4.27 | 9.01 | 13.41 | 6.93 | 6.59 | 11.71 | 4.15 | 3.66 |
Price to Tangible BV |
6.52 | 11.31 | 4.31 | 9.04 | 13.44 | 6.93 | 6.60 | 13.80 | 4.96 | 4.02 |
EV/Sales |
161.81 | 27.14 | 7.03 | 16.52 | 17.61 | 6.66 | 4.30 | 6.36 | 2.39 | 3.43 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 9.63 | 33.08 |
EV/Operating CF |
(13.46) | (15.57) | (9.40) | (37.05) | (57.13) | (25.67) | (19.49) | 276.42 | 14.49 | 33.48 |
EV/FCF |
(13.36) | (15.51) | (9.28) | (36.78) | (54.11) | (25.44) | (19.30) | (197.73) | 19.51 | (39.55) |
Quick Ratio |
12.59 | 7.34 | 8.42 | 9.83 | 6.44 | 6.10 | 3.82 | 2.13 | 2.18 | 3.49 |
Current Ratio |
12.87 | 7.62 | 8.83 | 10.16 | 6.77 | 6.43 | 4.04 | 2.42 | 2.38 | 3.83 |
Net Debt/EBITDA |
1.95 | 1.18 | 1.93 | 2.82 | 2.24 | 3.16 | 1.86 | 5.82 | (3.18) | (7.37) |
Debt/Assets |
0.03% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.04 | 0.26 | 0.48 | 0.51 | 0.56 | 0.65 | 0.80 | 1.09 | 0.99 | 0.78 |
Operating CF/Net income |
0.77 | 0.75 | 0.68 | 0.64 | 0.48 | 0.75 | 0.53 | (0.27) | 0.70 | 0.28 |
Capex/Depreciation |
(4.96) | (0.34) | (0.87) | 1.33 | (1.72) | (0.20) | 0.00 | 20.22 | (0.08) | (0.74) |
| (75.58%) | (67.80%) | (60.22%) | (39.93%) | (42.47%) | (28.75%) | (45.89%) | (14.73%) | 38.89% | 39.89% | |
| (69.32%) | (61.21%) | (53.03%) | (35.55%) | (35.97%) | (22.64%) | (33.54%) | (9.17%) | 23.39% | 28.42% | |
ROIC |
0.00% | 0.00% | (2,782.02%) | (9,032.28%) | 0.00% | (527.66%) | 0.00% | 0.00% | 0.00% | 16.07% |
Return on Tangible Assets |
(53.38%) | (88.47%) | (52.19%) | (34.16%) | (45.36%) | (31.69%) | (55.62%) | (16.72%) | 41.35% | 49.34% |
Average Days of Receivables |
150.37 | 53.86 | 45.32 | 40.77 | 41.55 | 49.26 | 44.51 | 51.43 | 39.90 | 50.49 |
Research and Development Expense of Revenue |
572.87% | 119.45% | 83.63% | 70.89% | 72.24% | 49.45% | 69.91% | 48.40% | 31.66% | 30.69% |
Selling, General and Administrative Expense of Revenue |
1,075.85% | 204.21% | 118.74% | 96.04% | 87.98% | 81.80% | 71.36% | 55.97% | 50.99% | 51.23% |
Intangible Assets out of Total Assets |
0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.09 | 0.10 | 0.07 |
Share Based Compensation of Revenue |
318.88% | 60.47% | 36.44% | 24.26% | 19.11% | 13.14% | 13.19% | 9.14% | 7.00% | 4.87% |
Graham Net Nets |
0.15 | 0.09 | 0.23 | 0.11 | 0.07 | 0.12 | 0.12 | 0.06 | 0.16 | 0.16 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 11.63 | 19.51 |
Earnings Yield |
(8.13%) | (7.72%) | (12.06%) | (3.74%) | (3.37%) | (4.50%) | (8.21%) | (1.24%) | 7.41% | 8.69% |
Free Cash Flow Yield |
(6.30%) | (5.86%) | (8.28%) | (2.42%) | (1.71%) | (3.38%) | (4.36%) | (0.46%) | 3.85% | (2.07%) |
Revenue per Share |
0.15 | 1.02 | 1.77 | 2.30 | 2.81 | 3.02 | 3.20 | 4.43 | 5.78 | 6.36 |
Operating CF per Share |
(1.80) | (1.78) | (1.32) | (1.03) | (0.87) | (0.78) | (0.71) | 0.10 | 0.95 | 0.65 |
Capex per Share |
(0.08) | (0.01) | (0.02) | (0.01) | (0.05) | (0.01) | 0.00 | (0.24) | 0.00 | (0.03) |
Free Cash Flow per Share |
(1.88) | (1.78) | (1.34) | (1.03) | (0.91) | (0.79) | (0.71) | (0.14) | 0.95 | 0.62 |
Cash per Share |
4.57 | 2.78 | 3.74 | 4.74 | 4.02 | 3.24 | 2.58 | 2.68 | 4.56 | 4.87 |
Shareholders Equity per Share |
4.47 | 2.73 | 3.78 | 4.75 | 3.99 | 3.37 | 2.48 | 2.64 | 4.42 | 7.29 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
4.47 | 2.73 | 3.78 | 4.75 | 3.99 | 3.37 | 2.48 | 2.64 | 4.42 | 7.29 |
Free Cash Flow |
(217.91) | (218.57) | (169.57) | (152.26) | (143.75) | (126.78) | (114.03) | (23.35) | 157.20 | 105.15 |
Working Capital |
505.31 | 324.45 | 466.54 | 685.42 | 611.65 | 521.76 | 382.31 | 361.87 | 543.45 | 785.00 |
Capital Expenditures |
(9.51) | (0.81) | (2.10) | (1.13) | (7.59) | (1.12) | — | (40.05) | (0.52) | (4.69) |
Net Current Asset Value |
505.16 | 324.26 | 464.98 | 676.20 | 562.01 | 458.60 | 320.54 | 298.92 | 483.36 | 725.31 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 9.90 | 35.08 |
Capex to Sales |
0.55 | 0.01 | 0.01 | 0.00 | 0.02 | 0.00 | 0.00 | 0.06 | 0.00 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 13.18 | 42.90 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.62 | 0.91 | 0.73 | (0.27) | 0.48 | 0.71 | (0.12) | (0.43) | 1.56 | 0.84 |
Cash ROIC |
(20.80%) | (32.30%) | (17.80%) | (10.90%) | (11.42%) | (11.94%) | (13.95%) | (2.68%) | 10.56% | 5.14% |
Accounts Receivable Turnover |
3.95 | 9.77 | 9.68 | 10.33 | 10.02 | 8.37 | 8.06 | 8.78 | 9.25 | 8.47 |
Accounts Payable Turnover |
1.10 | 1.43 | 2.07 | 2.18 | 1.30 | 2.49 | 1.04 | 2.75 | 4.85 | 6.57 |
Inventory Turnover |
0.65 | 1.93 | 2.66 | 2.18 | 1.27 | 2.18 | 1.40 | 1.96 | 2.83 | 3.14 |
Average Days of Payables |
464.35 | 353.30 | 93.40 | 232.37 | 303.59 | 131.12 | 457.63 | 153.78 | 72.21 | 44.72 |
Days of Inventory on Hand |
495.57 | 211.03 | 120.03 | 204.03 | 346.09 | 150.28 | 238.26 | 313.99 | 97.89 | 142.19 |
Average Receivables |
4.39 | 12.79 | 23.11 | 32.83 | 44.08 | 57.81 | 64.21 | 82.72 | 103.52 | 126.46 |
Average Payables |
2.79 | 6.35 | 5.98 | 5.19 | 7.86 | 7.68 | 9.81 | 15.14 | 16.87 | 13.55 |
Average Inventory |
4.71 | 4.71 | 4.66 | 5.21 | 8.01 | 8.78 | 7.26 | 21.23 | 28.88 | 28.31 |
Average Assets |
391.52 | 472.83 | 462.35 | 661.69 | 782.90 | 741.37 | 643.97 | 668.38 | 968.36 | 1,375.98 |
Average Common Equity |
359.09 | 426.85 | 407.18 | 589.11 | 663.07 | 583.95 | 470.65 | 416.08 | 582.27 | 980.09 |
Columns are period end dates